Latest Articles

Publication Date
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Business Wire

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Business Wire

Published: May 18, 2026, 10:45 a.m.
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Yahoo! Finance Canada

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Yahoo! Finance …

Published: May 18, 2026, 10:45 a.m.
Single-cell profiling and machine learning identify cuproptosis-related fibroblast subpopulations and fibrogenesis modulator AEBP1 in endometriosis.

Endometriosis is characterized by progressive fibrosis and limited therapeutic options. Cuproptosis, a copper-dependent form of regulated cell death, has been implicated in multiple pathological conditions, but its relevance to fibroblast-mediated …

Published: May 18, 2026, midnight
HSD11B1 suppresses ferroptosis in endometrial stromal cells through the JUND/IL-10 axis to promote endometriosis progression.

Endometriosis (EMs) is a common gynecological disorder characterized by ectopic endometrial tissue growth, leading to chronic inflammation and pelvic pain. Despite its high prevalence, the molecular mechanisms underlying EMs remain …

Published: May 18, 2026, midnight
GSK preps lawsuit against US firm AnaptysBioover endometrial cancer drug - MSN

GSK preps lawsuit against US firm AnaptysBioover endometrial cancer drug MSN

Published: May 17, 2026, 7:18 p.m.
Endometriosis and ovarian cancer: epidemiological evidence, molecular insights, and clinical decision-making.

Endometriosis, particularly ovarian endometrioma, is associated with a 2-fold increased risk of ovarian cancer (OC), especially the clear cell and endometrioid subtypes. However, the absolute lifetime risk of OC in …

Published: May 17, 2026, midnight
The Four Types of Therapy for Second-Line Endometrial Cancer - CancerNetwork

The Four Types of Therapy for Second-Line Endometrial Cancer CancerNetwork

Published: May 16, 2026, 2:04 p.m.
Nuclear factor IX promotes endometriosis progression through transcriptional activation of tetraspanin-2.

Endometriosis is a benign yet aggressive disease characterized by enhanced proliferation and invasion of ectopic endometrial tissue. Identifying upstream regulators that co-regulate these processes will provide novel insights into endometriosis …

Published: May 16, 2026, midnight
Navigating the Evolving Landscape of Second-Line Endometrial Cancer Care - CancerNetwork

Navigating the Evolving Landscape of Second-Line Endometrial Cancer Care CancerNetwork

Published: May 15, 2026, 2:05 p.m.
Common Gynecologic Issues in Patients Post-Kidney Transplantation.

Advances in kidney transplantation have transformed survival and quality of life for women with end-stage renal disease, necessitating a focus on long-term health care for this population. Female kidney transplant …

Published: May 15, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!